Loading news...
Bavarian Nordic A/S (BVNKF) is heading into another period of transition after Chief Executive Paul Chaplin said he will step down for personal reasons at the e
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness. 2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions.
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure.
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.
COPENHAGEN, Denmark, January 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.
COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as part of the annual remuneration as laid out in the Remuneration Policy, adopted at the annual general meeting. Members of the Executive Management are granted performance restricted stock units (Performance RSUs), subject to the successful achievement of relevant Key Performance Indicators (KPI's), measured over a three-year performance period from grant. Furthermore, and also in accordance with the Remuneration Policy, a warrant program has been established for selected other employees in the Bavarian Nordic Group, entitling the warrant holders to subscribe for new shares in the Company, subject to certain terms, including a three-year vesting period.
Bavarian Nordic A/S (OTCPK:BVNRY) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Paul Chaplin - CEO & President Henrik Juuel - CFO & Executive VP Conference Call Participants Romy O'Connor - Van Lanschot Kempen NV Thomas Bowers - SEB, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Bavarian Nordic Third Quarterly Report for the 9-month period ended 30th of September 2025 Conference Call on Webcast.
Danish vaccine maker Bavarian Nordic said on Thursday Luc Debruyne will step down as chair, days after a takeover attempt by Nordic Capital and Permira collapsed.
COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025.
COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025.
Innosera, a consortium led by Nordic Capital and Permira, failed to achieve the required level of support from shareholders for its planned takeover of Bavarian Nordic and will withdraw its bid, Bavarian Nordic said on Thursday.
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, announced yesterday, and the Public Preparedness business.
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic announced on Friday a new contract with the European Commission, allowing countries across Europe to buy up to eight million doses of its smallpox and mpox vaccine over the next four years.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
ATP's rejection of a sweetened bid from private-equity firms for the vaccine maker casts doubt over whether the deal will go through.
Bavarian Nordic said on Wednesday a consortium led by Nordic Capital and Permira has raised its offer price for the vaccine maker to 250 Danish crowns ($38.94) after its initial bid was not accepted by a sufficient number of investors.
Bavarian Nordic A/S (OTCPK:BVNKF) Q2 2025 Earnings Conference Call August 22, 2025 8:00 AM ET Company Participants Henrik Juuel - CFO & Executive VP Paul John Chaplin - CEO & President Rolf Sass Sorensen - Vice President of Investor Relations Conference Call Participants Romy O'Connor - Unidentified Company Thomas Schultz Bowers - SEB, Research Division Operator Good day, and thank you for standing by. Welcome to the Bavarian Nordic Half Year Report Q2 for the 6 months period ended 30th of June 2025 conference call.
Bavarian Nordic , subject of a takeover offer valuing the vaccine maker at about 19 billion Danish crowns ($3 billion), reported a higher than expected revenue for the second quarter on Friday, citing a strong performance in both its travel health and public preparedness businesses.